New study aims to improve monitoring of rare childhood muscle disease
NCT ID NCT05224778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for children up to 4 years old with congenital myotonic dystrophy type 1 (CDM). Researchers want to find better ways to measure how the disease affects motor skills and language, and to identify biological markers. The goal is to improve future clinical trials and care for children with CDM.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centro Clinico NeMO
RECRUITINGMilan, 20162, Italy
-
University of California, Los Angeles
RECRUITINGLos Angeles, California, 90095, United States
-
University of Kansas Medical Center
RECRUITINGFairway, Kansas, 66205, United States
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we measure the progression of childhood myotonic dystrophy well enough to test new therapies?
- Scientists hunt for biomarkers to unlock DM1 treatments
- No travel needed: new study uses video calls to uncover genetic secrets of childhood muscle disease
- Join the fight: new registry connects muscle disease patients with scientists
- New drug shows promise for rare muscle disease in kids
- Experimental drug tideglusib tested for rare muscle disease